[Adverse effects associated with influenza vaccine in pediatrics].
Identifieur interne : 000686 ( Main/Exploration ); précédent : 000685; suivant : 000687[Adverse effects associated with influenza vaccine in pediatrics].
Auteurs : V. Martín Moreno [Espagne] ; M R Molina Cabrerizo ; M J Sotillo Rinc N ; C. G Mez G Mez ; J. Alvarez G MezSource :
- Revista espanola de salud publica [ 1135-5727 ]
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Calendrier vaccinal (MeSH), Enfant (MeSH), Espagne (MeSH), Facteurs âges (MeSH), Femelle (MeSH), Humains (MeSH), Mâle (MeSH), Relation dose-effet des médicaments (MeSH), Vaccination (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Vaccins antigrippaux.
- Adolescent, Calendrier vaccinal, Enfant, Espagne, Facteurs âges, Femelle, Humains, Mâle, Relation dose-effet des médicaments, Vaccination.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- geographic : Spain.
- Adolescent, Age Factors, Child, Dose-Response Relationship, Drug, Female, Humans, Immunization Schedule, Male, Vaccination.
Abstract
BACKGROUND
The difficulties which exist in order to value correctly the morbimortality caused by influenza during the childhood and the limitations of the proper vaccine make that the use of this vaccination is still limited in this phase. The objective of the present study is to value the adverse reactions associated to the influenza immunization in children.
METHODS
Prospective study, carried out in the campaigns 92/93, 93/94 97/98 on 105 children of Navalcarnero with split-virion influenza vaccine with vaccinal strains recommended by the OMS. All the doses are administered by a nurse who also carries out the postimmunization-controls after 72 hours. The adverse reactions are valued, like the zone of injection, sex, age, the previous vaccination and the collection of data by telephone or in consultation.
RESULTS
Of global form (318 doses), on a local level appears a reaction of 10.7%, in form of erythema (8.5%), induration (7.9%) and pain (only 97/98, 13.9%) and on a systemic level appears a reaction of 11.9%, in form of rhinorrhea (3.1%), general discomfort (2.5%), fever (2.5%), muscular pains (1.6%) and cough (1.6%). In a 89.5% the systemic effects disappear during the first 48 hours. In no case medical consultation was precised.
CONCLUSIONS
The vaccine is safe. The adverse reactions that may appear are scarce, slight and well tolerated. There do not exist significant differences in terms of age, sex, the previous vaccination or the collection of the results by telephone or in consultation. The gluteus presents greater local reactogenicity that the deltoidal zone.
PubMed: 9810837
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Adverse effects associated with influenza vaccine in pediatrics].</title><author><name sortKey="Martin Moreno, V" sort="Martin Moreno, V" uniqKey="Martin Moreno V" first="V" last="Martín Moreno">V. Martín Moreno</name><affiliation wicri:level="3"><nlm:affiliation>Centro de Salud San Fernando II, Azorín, Móstoles, Madrid.</nlm:affiliation><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><wicri:orgArea>Centro de Salud San Fernando II, Azorín, Móstoles</wicri:orgArea></affiliation></author><author><name sortKey="Molina Cabrerizo, M R" sort="Molina Cabrerizo, M R" uniqKey="Molina Cabrerizo M" first="M R" last="Molina Cabrerizo">M R Molina Cabrerizo</name></author><author><name sortKey="Sotillo Rinc N, M J" sort="Sotillo Rinc N, M J" uniqKey="Sotillo Rinc N M" first="M J" last="Sotillo Rinc N">M J Sotillo Rinc N</name></author><author><name sortKey="G Mez G Mez, C" sort="G Mez G Mez, C" uniqKey="G Mez G Mez C" first="C" last="G Mez G Mez">C. G Mez G Mez</name></author><author><name sortKey="Alvarez G Mez, J" sort="Alvarez G Mez, J" uniqKey="Alvarez G Mez J" first="J" last="Alvarez G Mez">J. Alvarez G Mez</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998 Jul-Aug</date><idno type="RBID">pubmed:9810837</idno><idno type="pmid">9810837</idno><idno type="wicri:Area/Main/Corpus">00688</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00688</idno><idno type="wicri:Area/Main/Curation">000688</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000688</idno><idno type="wicri:Area/Main/Exploration">000688</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Adverse effects associated with influenza vaccine in pediatrics].</title><author><name sortKey="Martin Moreno, V" sort="Martin Moreno, V" uniqKey="Martin Moreno V" first="V" last="Martín Moreno">V. Martín Moreno</name><affiliation wicri:level="3"><nlm:affiliation>Centro de Salud San Fernando II, Azorín, Móstoles, Madrid.</nlm:affiliation><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName><wicri:orgArea>Centro de Salud San Fernando II, Azorín, Móstoles</wicri:orgArea></affiliation></author><author><name sortKey="Molina Cabrerizo, M R" sort="Molina Cabrerizo, M R" uniqKey="Molina Cabrerizo M" first="M R" last="Molina Cabrerizo">M R Molina Cabrerizo</name></author><author><name sortKey="Sotillo Rinc N, M J" sort="Sotillo Rinc N, M J" uniqKey="Sotillo Rinc N M" first="M J" last="Sotillo Rinc N">M J Sotillo Rinc N</name></author><author><name sortKey="G Mez G Mez, C" sort="G Mez G Mez, C" uniqKey="G Mez G Mez C" first="C" last="G Mez G Mez">C. G Mez G Mez</name></author><author><name sortKey="Alvarez G Mez, J" sort="Alvarez G Mez, J" uniqKey="Alvarez G Mez J" first="J" last="Alvarez G Mez">J. Alvarez G Mez</name></author></analytic><series><title level="j">Revista espanola de salud publica</title><idno type="ISSN">1135-5727</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Age Factors (MeSH)</term><term>Child (MeSH)</term><term>Dose-Response Relationship, Drug (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Immunization Schedule (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Male (MeSH)</term><term>Spain (MeSH)</term><term>Vaccination (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Calendrier vaccinal (MeSH)</term><term>Enfant (MeSH)</term><term>Espagne (MeSH)</term><term>Facteurs âges (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Relation dose-effet des médicaments (MeSH)</term><term>Vaccination (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Age Factors</term><term>Child</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Male</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Calendrier vaccinal</term><term>Enfant</term><term>Espagne</term><term>Facteurs âges</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Relation dose-effet des médicaments</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The difficulties which exist in order to value correctly the morbimortality caused by influenza during the childhood and the limitations of the proper vaccine make that the use of this vaccination is still limited in this phase. The objective of the present study is to value the adverse reactions associated to the influenza immunization in children.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Prospective study, carried out in the campaigns 92/93, 93/94 97/98 on 105 children of Navalcarnero with split-virion influenza vaccine with vaccinal strains recommended by the OMS. All the doses are administered by a nurse who also carries out the postimmunization-controls after 72 hours. The adverse reactions are valued, like the zone of injection, sex, age, the previous vaccination and the collection of data by telephone or in consultation.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Of global form (318 doses), on a local level appears a reaction of 10.7%, in form of erythema (8.5%), induration (7.9%) and pain (only 97/98, 13.9%) and on a systemic level appears a reaction of 11.9%, in form of rhinorrhea (3.1%), general discomfort (2.5%), fever (2.5%), muscular pains (1.6%) and cough (1.6%). In a 89.5% the systemic effects disappear during the first 48 hours. In no case medical consultation was precised.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The vaccine is safe. The adverse reactions that may appear are scarce, slight and well tolerated. There do not exist significant differences in terms of age, sex, the previous vaccination or the collection of the results by telephone or in consultation. The gluteus presents greater local reactogenicity that the deltoidal zone.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9810837</PMID><DateCompleted><Year>1998</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1135-5727</ISSN><JournalIssue CitedMedium="Print"><Volume>72</Volume><Issue>4</Issue><PubDate><MedlineDate>1998 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Revista espanola de salud publica</Title><ISOAbbreviation>Rev. Esp. Salud Publica</ISOAbbreviation></Journal><ArticleTitle>[Adverse effects associated with influenza vaccine in pediatrics].</ArticleTitle><Pagination><MedlinePgn>319-29</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The difficulties which exist in order to value correctly the morbimortality caused by influenza during the childhood and the limitations of the proper vaccine make that the use of this vaccination is still limited in this phase. The objective of the present study is to value the adverse reactions associated to the influenza immunization in children.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Prospective study, carried out in the campaigns 92/93, 93/94 97/98 on 105 children of Navalcarnero with split-virion influenza vaccine with vaccinal strains recommended by the OMS. All the doses are administered by a nurse who also carries out the postimmunization-controls after 72 hours. The adverse reactions are valued, like the zone of injection, sex, age, the previous vaccination and the collection of data by telephone or in consultation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of global form (318 doses), on a local level appears a reaction of 10.7%, in form of erythema (8.5%), induration (7.9%) and pain (only 97/98, 13.9%) and on a systemic level appears a reaction of 11.9%, in form of rhinorrhea (3.1%), general discomfort (2.5%), fever (2.5%), muscular pains (1.6%) and cough (1.6%). In a 89.5% the systemic effects disappear during the first 48 hours. In no case medical consultation was precised.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The vaccine is safe. The adverse reactions that may appear are scarce, slight and well tolerated. There do not exist significant differences in terms of age, sex, the previous vaccination or the collection of the results by telephone or in consultation. The gluteus presents greater local reactogenicity that the deltoidal zone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martín Moreno</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centro de Salud San Fernando II, Azorín, Móstoles, Madrid.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina Cabrerizo</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Sotillo Rincón</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Gómez Gómez</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Alvarez Gómez</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Efectos adversos asociados a la vacunación antigripal en pediatría.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Salud Publica</MedlineTA><NlmUniqueID>9600212</NlmUniqueID><ISSNLinking>1135-5727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>11</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>11</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9810837</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country><region><li>Communauté de Madrid</li></region><settlement><li>Madrid</li></settlement></list><tree><noCountry><name sortKey="Alvarez G Mez, J" sort="Alvarez G Mez, J" uniqKey="Alvarez G Mez J" first="J" last="Alvarez G Mez">J. Alvarez G Mez</name><name sortKey="G Mez G Mez, C" sort="G Mez G Mez, C" uniqKey="G Mez G Mez C" first="C" last="G Mez G Mez">C. G Mez G Mez</name><name sortKey="Molina Cabrerizo, M R" sort="Molina Cabrerizo, M R" uniqKey="Molina Cabrerizo M" first="M R" last="Molina Cabrerizo">M R Molina Cabrerizo</name><name sortKey="Sotillo Rinc N, M J" sort="Sotillo Rinc N, M J" uniqKey="Sotillo Rinc N M" first="M J" last="Sotillo Rinc N">M J Sotillo Rinc N</name></noCountry><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Martin Moreno, V" sort="Martin Moreno, V" uniqKey="Martin Moreno V" first="V" last="Martín Moreno">V. Martín Moreno</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000686 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000686 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9810837
|texte= [Adverse effects associated with influenza vaccine in pediatrics].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9810837" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |